RxDoctor Payments DataLook up a doctor →

Dane Dickson, MD

Hematology & Oncology · Rexburg, IDNPI 1669497194

Payments from drug & device makers

$21,155in general payments, 2019–2025

Across 517 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$9K
  • Advanced Accelerator Applications$3K
  • Pfizer$820
  • Novartis$752
  • AstraZeneca$716
  • E.r. Squibb & Sons, L.L.C.$646
  • plus $6K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences3$8,671
Advanced Accelerator Applications1$3,000
Pfizer65$820
Novartis27$752
AstraZeneca(2 entities)37$716
E.r. Squibb & Sons, L.L.C.47$646
Johnson & Johnson(2 entities)27$570
Astellas Pharma US Inc26$549
Merck26$460
Sanofi23$441
Daiichi Sankyo Inc.23$435
Amgen22$372
Eisai Inc.18$304
Genentech USA, Inc.16$275
Gilead(2 entities)10$260
Bristol Myers Squibb12$219
AbbVie11$213
Lilly USA, LLC11$187
Boehringer Ingelheim8$156
Coherus Oncology, Inc.2$151
Tersera Therapeutics LLC6$142
AVEO Pharmaceuticals, Inc.3$136
EMD Serono, Inc.8$133
Rigel Pharmaceuticals, Inc.5$100
GSK5$83
Bayer5$79
Deciphera Pharmaceuticals Inc.3$77
Incyte Corporation4$70
Takeda Pharmaceuticals U.S.A., Inc.3$61
Genmab U.S., Inc.3$58
Agios Pharmaceuticals, Inc.3$57
Seagen Inc.3$56
Regeneron Healthcare Solutions, Inc.3$52
Ipsen Biopharmaceuticals, Inc3$52
Pharmacyclics LLC, An Abbvie Company3$51
Geron Corporation2$47
Sobi, Inc3$44
Taiho Oncology, Inc.2$44
Sumitomo Pharma America, Inc.2$42
Servier Pharmaceuticals LLC2$37
Blueprint Medicines Corporation2$36
Springworks Therapeutics, Inc.2$35
Myovant Sciences Inc.2$34
Legend Biotech USA Inc.1$33
Adaptive Biotechnologies Corporation1$33
Puma Biotechnology, Inc.2$32
Dendreon Pharmaceuticals LLC1$28
Beigene USA, Inc.2$28
Medtronic1$24
Iovance Biotherapeutics, Inc.1$22
Syndax Pharmaceuticals, Inc.1$22
Secura Bio, Inc.3$21
Spectrum Pharmaceuticals Inc.1$20
Karyopharm Therapeutics Inc.1$20
Azurity Pharmaceuticals, Inc.1$19
Mirati Therapeutics, Inc.1$18
Jazz Pharmaceuticals Inc.1$16
Novocure Inc.1$15
Clovis Oncology, Inc.1$14
Alnylam Pharmaceuticals Inc.1$14

How this compares

$21,155 in reported general payments places this provider in the 65th percentile of 34 hematology & oncology providers in Idaho.

See all hematology & oncology providers in Idaho →

Medicare billing

Part B allowed, 2024
$25,897
Medicare patients
137
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Rexburg

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →